Citations

Showing 10 of 108119 citations.

Escalating incidence of infective endocarditis in Europe in the 21st century
Talha, Khawaja M. , Thornhill, Martin H. , Arshad, Verda , Tariq, Wajeeha , Tleyjeh, Imad M, Scott, Christopher G. , Hyun, Meredith C, Bailey, Kent R. , Anavekar, Nandan S., Palraj, Raj , Tleyjeh, Imad M. , Scott, Christopher , Thornhill, M H , Tleyjeh, Imad M , Palraj, Raj , Baddour, Larry M. , Hyun, Meredith C, Sohail, M. Rizwan , DeSimone, Daniel C. , Dayer, Mark

Mayo Clinic

Open Heart | October 20, 2021 | Volume: 8 | Issue: 2 | Pages: e001846

10.1136/openhrt-2021-001846 | PMID 34670832 Get It

Aim To provide a contemporary analysis of incidence trends of infective endocarditis (IE) with its changing epidemiology over the past two decades in Europe. Methods A systematic review was conducted at the Mayo Clinic, Rochester. Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus and Web of Science were searched for studies published between 1 January 2000 and 30 November 2020. All studies were independently reviewed by four referees and those that included a population-based incidence of IE in patients, irrespective of age, in Europe were included. Least squares regression was used to estimate pooled temporal trends in IE incidence. Results Of 9138 articles screened, 18 studies were included in the review. Elderly men predominated in all studies. IE incidence increased 4.1% per year (95% CI 1.8% to 6.4%) in the pooled regression analysis of eight studies that included comprehensive and consistent trends data. When trends data were weighted according to population size of individual countries, an increase in yearly incidence of 0.27 cases per 100 000 people was observed. Staphylococci and streptococci were the most common pathogens identified. The rate of surgical intervention ranged from 10.2% to 60.0%, and the rate of inpatient mortality ranged from 14.3% to 17.5%. In six studies that examined the rate of injection drug use, five of them reported a rate of less than 10%. Conclusion Based on findings from our systematic review, IE incidence in Europe has doubled over the past two decades in Europe. Multiple factors are likely responsible for this striking increase. Trial registeration number CRD42020191196.
Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
Verbrugge, Frederik H. , Reddy, Yogesh N.V. , Eleid, Mackram F. , Lin, Grace , Borlaug, Barry A. , Borlaug, Barry A , Nishimura, Rick , Verbrugge, Frederik H , Burkhoff, Daniel

Mayo Clinic

Open Heart | October 20, 2021 | Volume: 8 | Issue: 2 | Pages: e001701

10.1136/openhrt-2021-001701 | PMID 34670831 Get It

Objective Mild aortic valve stenosis (AS) and aortic valve (AV) sclerosis are associated with diastolic dysfunction and increased mortality in the general population. This study specifically investigated the impact of mild AV disease in heart failure with preserved ejection fraction (HFpEF). Methods Consecutive patients hospitalised with HFpEF (n=370) underwent assessment of cardiac structure and function and long-term clinical follow-up. Results In the study cohort, 111 had mild AS (30%), 104 AV sclerosis (28%) and 155 a non-calcified AV (42%). Mild-to-moderate AV regurgitation (AR) was present in 64 (17%). Compared with patients with a normal AV, those with AV disease were older, with worse renal function and more atrial fibrillation. E/e′ increased from non-calcified AV to AV sclerosis to mild AS (13.8 (10.8–16.8) vs 15.0 (10.9–20.0) vs 18.0 (12.7–23.3), respectively; p<0.001)). Left ventricular diastolic pressure–volume relationships were shifted leftwards in patients with AS and AV sclerosis, but not influenced by AR. The left ventricular end-diastolic volume normalised at 20 mm Hg was 117±34 mL, 106±30 mL and 112±30 mL in non-calcified AV, AV sclerosis and mild AS, respectively (p=0.023), while 112±32 mL in mild-to-moderate AR. Over 30 months (IQR, 8–61 months), 247 patients died (67%). The presence of mild AV disease was associated with increased mortality, but this was no longer significant after adjusting for age and sex. Conclusions Low-grade AV disease is common among patients hospitalised for HFpEF and is associated with older age, atrial arrhythmia, renal dysfunction, higher left heart filling pressures and increased left ventricular chamber stiffness.
The Kidney in Normal Aging
Đenić, Aleksandar , Glassock, Richard J. , Rule, Andrew D. , Rule, Andrew D , Denic, Aleksandar

Mayo Clinic

Clinical Journal of the American Society of Nephrology | October 20, 2021 | Volume: 17 | Issue: 1 | Pages: 137-139

10.2215/cjn.10580821 | PMID 34670799 Get It

Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder
Sosero, Yuri L., Yu, Eric, Estiar, Mehrdad A., Krohn, Lynne, Mufti, Kheireddin, Rudakou, Uladzislau, Ruskey, Jennifer A., Asayesh, Farnaz, Laurent, Sandra B., Spiegelman, Dan, Trempe, Jean-François, Quinnell, Timothy G., Oscroft, Nicholas, Arnulf, Isabelle, Montplaisir, Jacques Y., Gagnon, Jean-François, Desautels, Alex, Dauvilliers, Yves, Gigli, Gian Luigi, Valente, Mariarosaria, Janes, Francesco, Bernardini, Andrea, Sonka, Karel, Kemlink, David, Oertel, Wolfgang, Janzen, Annette, Plazzi, Giuseppe, Antelmi, Elena, Biscarini, Francesco, Figorilli, Michela, Puligheddu, Monica, Mollenhauer, Brit, Trenkwalder, Claudia, Sixel-Döring, Friederike, Cock, Valérie Cochen De, Monaca, Christelle Charley, Heidbreder, Anna, Ferini-Strambi, Luigi, Dijkstra, Femke, Viaene, Mineke, Abril, Beatriz, Boeve, Bradley F., Postuma, Ronald B., Rouleau, Guy A., Ibrahim, Abubaker, Stefani, Ambra, Högl, Birgit, Hu, Michele T.M., Gan-Or, Ziv, Arnulf, Isabelle , Stefani, Ambra , Heidbreder, Anna , Puligheddu, Monica , Figorilli, Michela , Janes, Francesco , Bernardini, Andrea , Ibrahim, Abubaker , Biscarini, Francesco , Stefani, Ambra , Bernardini, Andrea , Arnulf, Isabelle , Ibrahim, Abubaker , Janes, Francesco , Figorilli, Michela , Puligheddu, Monica , Biscarini, Francesco , Heidbreder, Anna , Sosero, Yuri L., Yu, Eric, Estiar, Mehrdad A., Krohn, Lynne, Mufti, Kheireddin, Rudakou, Uladzislau, Ruskey, Jennifer A., Asayesh, Farnaz, Laurent, Sandra B., Spiegelman, Dan, Trempe, Jean-François, Quinnell, Timothy G., Oscroft, Nicholas, Montplaisir, Jacques Y., Gagnon, Jean-François, Desautels, Alex, Dauvilliers, Yves, Gigli, Gian Luigi, Valente, Mariarosaria, Sonka, Karel, Kemlink, David, Oertel, Wolfgang, Janzen, Annette, Plazzi, Giuseppe, Antelmi, Elena, Mollenhauer, Brit, Trenkwalder, Claudia, Sixel-Döring, Friederike, Cock, Valérie Cochen De, Monaca, Christelle Charley, Ferini-Strambi, Luigi, Dijkstra, Femke, Viaene, Mineke, Abril, Beatriz, Boeve, Bradley F., Postuma, Ronald B., Rouleau, Guy A., Ibrahim, Abubaker, Högl, Birgit, Hu, Michele T.M., Gan-Or, Ziv

Mayo Clinic

Journal of Parkinson's Disease | October 20, 2021 | Volume: 12 | Issue: 1 | Pages: 333-340

10.3233/jpd-212867 | PMID 34690151 Get It

Background: PSAP encodes saposin C, the co-activator of glucocerebrosidase, encoded by GBA. GBA mutations are associated with idiopathic/isolated REM sleep behavior disorder (iRBD), a prodromal stage of synucleinopathy. Objective: To examine the role of PSAP mutations in iRBD. Methods: We fully sequenced PSAP and performed Optimized Sequence Kernel Association Test in 1,113 iRBD patients and 2,324 controls. We identified loss-of-function (LoF) mutations, which are very rare in PSAP, in three iRBD patients and none in controls (uncorrected p = 0.018). Results: Two variants were stop mutations, p.Gln260Ter and p.Glu166Ter, and one was an in-frame deletion, p.332_333del. All three mutations have a deleterious effect on saposin C, based on in silico analysis. In addition, the two carriers of p.Glu166Ter and p.332_333del mutations also carried a GBA variant, p.Arg349Ter and p.Glu326Lys, respectively. The co-occurrence of these extremely rare PSAP LoF mutations in two (0.2%) GBA variant carriers in the iRBD cohort, is unlikely to occur by chance (estimated co-occurrence in the general population based on gnomAD data is 0.00035%). Although none of the three iRBD patients with PSAP LoF mutations have phenoconverted to an overt synucleinopathy at their last follow-up, all manifested initial signs suggestive of motor dysfunction, two were diagnosed with mild cognitive impairment and all showed prodromal clinical markers other than RBD. Their probability of prodromal PD, according to the Movement Disorder Society research criteria, was 98% or more. Conclusion: These results suggest a possible role of PSAP variants in iRBD and potential genetic interaction with GBA, which requires additional studies.
Sorbitol Is a Severity Biomarker for PMM2‐CDG with Therapeutic Implications
Ligezka, Anna N. , Radenkovic, Silvia , Saraswat, Mayank , Garapati, Kishore , Ranatunga, Wasantha , Yanaihara, Hitoshi, Preston, Graeme , Brucker, William , McGovern, Renee M., Cassiman, David , Johnsen, Christin , Lam, Christina , Edmondson, Andrew C. , Raymond, Kimiyo , Oglesbee, Devin , Pandey, Akhilesh , Reid, Joel M. , Muthusamy, Karthik , Morava, Eva , Pandey, Akhilesh , Oglesbee, Devin , Edmondson, Andrew C , Garapati, Kishore , Krzyściak, Wirginia , Muthusamy, Karthik , Mercimek‐Andrews, Saadet , Larson, Austin , Ghesquière, Bart , Witters, Peter , Perlstein, Ethan , Kozicz, Tamás , Morava, Éva

Mayo Clinic

Annals of Neurology | October 20, 2021 | Volume: 90 | Issue: 6 | Pages: 887-900

10.1002/ana.26245 | PMID 34652821 Get It

ObjectiveEpalrestat, an aldose reductase inhibitor increases phosphomannomutase (PMM) enzyme activity in a PMM2‐congenital disorders of glycosylation (CDG) worm model. Epalrestat also decreases sorbitol level in diabetic neuropathy. We evaluated the genetic, biochemical, and clinical characteristics, including the Nijmegen Progression CDG Rating Scale (NPCRS), urine polyol levels and fibroblast glycoproteomics in patients with PMM2‐CDG.MethodsWe performed PMM enzyme measurements, multiplexed proteomics, and glycoproteomics in PMM2‐deficient fibroblasts before and after epalrestat treatment. Safety and efficacy of 0.8 mg/kg/day oral epalrestat were studied in a child with PMM2‐CDG for 12 months.ResultsPMM enzyme activity increased post‐epalrestat treatment. Compared with controls, 24% of glycopeptides had reduced abundance in PMM2‐deficient fibroblasts, 46% of which improved upon treatment. Total protein N‐glycosylation improved upon epalrestat treatment bringing overall glycosylation toward the control fibroblasts’ glycosylation profile. Sorbitol levels were increased in the urine of 74% of patients with PMM2‐CDG and correlated with the presence of peripheral neuropathy, and CDG severity rating scale. In the child with PMM2‐CDG on epalrestat treatment, ataxia scores improved together with significant growth improvement. Urinary sorbitol levels nearly normalized in 3 months and blood transferrin glycosylation normalized in 6 months.InterpretationEpalrestat improved PMM enzyme activity, N‐glycosylation, and glycosylation biomarkers in vitro. Leveraging cellular glycoproteome assessment, we provided a systems‐level view of treatment efficacy and discovered potential novel biosignatures of therapy response. Epalrestat was well‐tolerated and led to significant clinical improvements in the first pediatric patient with PMM2‐CDG treated with epalrestat. We also propose urinary sorbitol as a novel biomarker for disease severity and treatment response in future clinical trials in PMM2‐CDG. ANN NEUROL 20219999:n/a–n/a
Neuropsychological Functioning in Alexander Disease: A Case Series
Kirsch, Alexandra C. , McCall, Dana M., Lange, Hadley, Renaud, Deborah L. , Brown, Tanya M. , Zaccariello, Michael J. , Renaud, Deborah , Brown, Tanya, McCall, Dana M.

Mayo Clinic

Child Neurology Open | October 20, 2021 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2329048x211048614 | PMID 34692893 Get It

Limited information is known about neuropsychological outcomes in Alexander disease, a rare leukodystrophy. Two pediatric cases are summarized. Case 1 (evaluations at 6, 7, 9, and 12 years of age) represents Type I Alexander disease with associated seizures. Case 2 (evaluations at 12, 13, and 16 years of age) represents Type II Alexander disease without additional complications. Case 1 experienced declines in intellectual functioning, visual motor skills, receptive vocabulary, verbal memory, and academic achievement. Case 2 experienced variable neurocognitive change and academic functioning, with average word reading and spelling. Verbal memory also remained intact. Taken together, individuals with Alexander disease may experience cognitive decline to variable degrees. Type I Alexander disease, associated with earlier onset and additional neurological complications, may presage greater cognitive decline than Type II. Due to variability in functioning over time, it is critical to follow individuals across development to make recommendations for educational and treatment planning.
Prognostic value of ABCDE stress echocardiography
Cortigiani, Lauro , Djordjevic‐Dikic, Ana , Rigo, Fausto , Simova, Iana , Morrone, D, Villari, Bruno, Picano, Eugenio , (SIECVI)., Stress Echo 2020 study group of the Italian Society of Echocardiography and Cardiovascular Imaging, Ciampi, Quirino , Zagatina, A , Wierzbowska‐Drabik, Karina , Haberka, Maciej , Boshchenko, A , Gaibazzi, Nicola , Barbieri, Andréa , Pellikka, Patricia A. , (SIECVI)., Stress Echo 2020 study group of the Italian Society of Echocardiography and Cardiovascular Imaging

Mayo Clinic

European Heart Journal | October 20, 2021 | Volume: 42 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehab724.047 Get It

Abstract Background Stress echocardiography (SE) was recently upgraded to the ABCDE protocol: step A, regional wall motion abnormalities; step B, B-lines; step C, left ventricular contractile reserve; step D, Doppler-based coronary flow velocity reserve in left anterior descending coronary artery; and step E, EKG-based heart rate reserve. Aim: to assess the prognostic value of ABCDE-SE in a prospective, large scale, multicenter, international, effectiveness study. Methods From July 2016 to November 2020, we enrolled 3,574 all-comers (age 65±11 years, 2,070 males, 58%; ejection fraction 60±10%) with known or suspected chronic coronary syndromes referred from 13 certified laboratories. All patients underwent ABCDE-SE. The employed stress modality was exercise (n=952, with semi-supine bike, n=887, or treadmill, n=65 with adenosine for step D) or pharmacological stress (n=2,622, with vasodilator, n=2,151; or dobutamine, n=471). SE response ranged from score 0 (all steps normal) to score 5 (all steps abnormal). All-cause death was the only end-point. Results Rate of abnormal results was 16% for A, 30% for B, 36% for C, 28% for D and 37% for E step. During a median follow-up of 21 months, 73 deaths occurred. At univariable analysis, predictors of all-cause mortality were step B (hazard ratio, HR: 2.621, 95% Confidence Intervals, CI: 1.654–4.152, p&lt;0.001), step D (HR: 2.578, 95% CI: 1.624–4.093, p&lt;0.001), and step E (HR: 2.955, 95% CI: 1.848–4.725, p&lt;0.001), but not step A (HR: 1.333, 95% CI: 0.731–2.430, p=0.349) and step C (HR1.581, 95% CI: 0.997–2.506, p=0.051). At multivariable analysis, ABCDE-SE was an independent predictor of mortality with score 3 (HR: 3.472, 95% CI: 1.483–8.135, p=0.004), 4 (HR: 4.045, 95% CI: 1.595–10.259, p=0.003) and 5 (HR: 5.678, 95% CI: 2.106–15.313, p=0.001) (Figure). Annual mortality rate ranged from 0.4% person/year for score 0 up to 2.4% person/year for score 5. Conclusion ABCDE-SE allows an effective risk stratification of patient global vulnerability. Funding Acknowledgement Type of funding sources: None. Survival curves based on ABCDE score
The Diagnostic, Prognostic and Therapeutic Role of miRNAs in Adrenocortical Carcinoma: A Systematic Review
Mytareli, Chrysoula, Delivanis, Danae A. , Athanassouli, Fani, Kalotychou, Vassiliki , Mantzourani, Marina , Kassi, Eva , Angelousi, Anna

Mayo Clinic

Biomedicines | October 20, 2021 | Volume: 9 | Issue: 11 | Pages: 1501

10.3390/biomedicines9111501 | PMID 34829730 Get It

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a dismal prognosis and a high rate of recurrence and mortality. Therapeutic options are limited. In some cases, the distinction of ACCs from benign adrenal neoplasms with the existing widely available pathological and histopathological tools is difficult. Thus, new biomarkers have been tested. We conducted a review of the recent literature on the advances of the diagnostic, prognostic and therapeutic role of miRNAs on ACC patients. More than 10 miRNAs validated by multiple studies were found to present a diagnostic and prognostic role for ACC patients, from which miR-483-5p and miR-195 were the most frequently met biomarkers. In particular, upregulation of miR-483-5p and downregulation of miR-195 were the most commonly validated molecular alterations. Unfortunately, data on the therapeutic role of miRNA are still scarce and limited mainly at the experimental level. Thus, the role of miRNA regulation in ACC remains an area of active research.
Ventricular Arrhythmias in Seniors with Heart Failure: Present Dilemmas and Therapeutic Considerations: A Systematic Review
Mene-Afejuku, Tuoyo O , Bamgboje, Abayomi O, Ogunniyi, Modele O, Akinboboye, Ola, Ibebuogu, Uzoma N, Ogunniyi, Modele O. , Mene-Afejuku, Tuoyo O , Bamgboje, Abayomi O, Akinboboye, Ola, Ibebuogu, Uzoma N

Mayo Clinic

Current Cardiology Reviews | October 20, 2021 | Volume: 18 | Issue: 2 | Pages: No page available

10.2174/1573403x17666211018095324 | PMID 34666644 Get It

Background: Heart Failure (HF) is a global public health problem, which affects over 23 million people worldwide. The prevalence of HF is higher among seniors in the USA and other developed countries. Ventricular Arrhythmias (VAs) account for 50% of deaths among patients with HF. We aim to elucidate the factors associated with VAs among seniors with HF, as well as therapies that may improve the outcomes. Methods: PubMed, Web of Science, Scopus, Cochrane Library databases, Science Direct, and Google Scholar were searched using specific keywords. The reference lists of relevant articles were searched for additional studies related to HF and VAs among seniors as well as associated outcomes. Results: The prevalence of VAs increases with worsening HF. A 24-hour Holter electrocardiogram may be useful in risk stratifying patients for device therapy if they do not meet the criterion of low ventricular ejection fraction. Implantable Cardiac Defibrillators (ICDs) are superior to anti-arrhythmic drugs in reducing mortality in patients with HF. Guideline-Directed Medical Therapy (GDMT) together with device therapy may be required to reduce symptoms. In general, the proportion of seniors on GDMT is low. A combination of ICDs and cardiac resynchronization therapy may improve outcomes in selected patients. Conclusion: Seniors with HF and VAs have high mortality even with the use of device therapy and GDMT. The holistic effect of device therapy on outcomes among seniors with HF is equivocal. More studies focused on seniors with advanced HF as well as therapeutic options are, therefore, required.